This study was conducted to compare the livertaxis of lactosaminated human growth hormone (hGH-L) with that of galactosyl human growth hormone (hGH-Gal), using radioactive tracer technique. hGH-L and hGH-Gal were first prepared. After hGH-L, hGH-Gal and hGH were labelled with 131I or 125I, the data on biodistribution in mice, imaging in rabbits and chicken were obtained. hGH-L and hGH-Gal had remarkable livertaxis and their percentages for uptake in liver were 68.83%-74.65% and 68.18%-74% respectively, which were about two times as high as that of hGH. All of the hepatic bindings were receptor-mediated. But, the synthesizing of hGH-L was more easy-to-do, more mild in reaction conditions, and more economical of raw material as compared with the synthesizing of hGH-Gal. Therefore, hGH-L is a more potential receptor-mediated hepatic targeting secreting somatomedian drug for treating dwarfism.